TCR2 Therapeutics (TCRR) PT Raised to $32 at Wedbush
- Wall Street comes off record highs ahead of big tech earnings
- Tesla (TSLA) Gains on Q2 Beat, Analysts Mostly Positive but Others Cautious
- China's Meituan (MPNGF) Plunges 17.6% to Push Hang Seng Index to 8-Month Lows as Heavy Selling Continues
- Dollar resumes climb as risk appetite fades; yuan, Aussie struggle
- Elon Musk Laid Into Apple (AAPL) During Tesla's (TSLA) Q2 Earnings Call
Wedbush analyst David Nierengarten raised the price target on TCR2 Therapeutics (NASDAQ: TCRR) to $32.00 (from $25.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Kotak Mahindra Bank Ltd. (KMB:IN) PT Raised to INR1,800 at UBS
- JD Logistics Inc (2618:HK) PT Lowered to HK$35 at Bernstein
- Westshore Terminals Investment Corp. (WTE:CN) (WTSHF) PT Raised to Cdn$22 at TD Securities
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!